Open AccessIbrutinib‐induced severe liver injury
Author(s) -
Nandikolla Amara G.,
Derman Olga,
Nautsch Deborah,
Liu Qiang,
Massoumi Hatef,
Venugopal Sangeetha,
Braunschweig Ira,
Janakiram Murali
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.881
Subject(s) - ibrutinib , medicine , bruton's tyrosine kinase , adverse effect , tyrosine kinase , tyrosine kinase inhibitor , refractory (planetary science) , cancer research , oncology , receptor , leukemia , chronic lymphocytic leukemia , cancer , physics , astrobiology
Key Clinical Message Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a patient with relapsed/refractory CLL.